Hays Advisory LLC Decreases Position in USANA Health Sciences Inc. (USNA)
Hays Advisory LLC decreased its stake in shares of USANA Health Sciences Inc. (NYSE:USNA) by 9.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 51,222 shares of the company’s stock after selling 5,467 shares during the period. USANA Health Sciences makes up approximately 1.2% of Hays Advisory LLC’s holdings, making the stock its 22nd largest position. Hays Advisory LLC owned about 0.43% of USANA Health Sciences worth $7,087,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Glenmede Trust Co. NA purchased a new stake in USANA Health Sciences during the second quarter valued at $349,000. First Trust Advisors LP purchased a new stake in USANA Health Sciences during the second quarter valued at $917,000. SG Americas Securities LLC purchased a new stake in USANA Health Sciences during the second quarter valued at $1,618,000. Emerald Acquisition Ltd. purchased a new stake in USANA Health Sciences during the second quarter valued at $4,619,000. Finally, Societe Generale purchased a new stake in USANA Health Sciences during the second quarter valued at $1,618,000. 42.12% of the stock is owned by institutional investors.
USANA Health Sciences Inc. (NYSE:USNA) traded up 0.08% during trading on Monday, hitting $125.50. 32,430 shares of the company were exchanged. The company has a 50-day moving average of $135.62 and a 200-day moving average of $129.11. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of 15.57 and a beta of 1.20. USANA Health Sciences Inc. has a 12 month low of $92.00 and a 12 month high of $150.00.
USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, October 25th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.27. The company earned $254.22 million during the quarter, compared to analysts’ expectations of $263.37 million. USANA Health Sciences had a net margin of 10.31% and a return on equity of 35.94%. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.92 earnings per share. Analysts forecast that USANA Health Sciences Inc. will post $8.13 EPS for the current year.
Several analysts have recently weighed in on the stock. DA Davidson increased their price target on shares of USANA Health Sciences from $135.00 to $150.00 and gave the company a “neutral” rating in a research note on Thursday, July 28th. Zacks Investment Research raised shares of USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $158.00 price target for the company in a research note on Saturday, July 30th.
In other news, insider Deborah Woo sold 1,058 shares of the business’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $140.00, for a total value of $148,120.00. Following the completion of the transaction, the insider now owns 2,537 shares of the company’s stock, valued at $355,180. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Myron W. Wentz sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $123.99, for a total transaction of $1,239,900.00. The disclosure for this sale can be found here. Company insiders own 57.00% of the company’s stock.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Stock Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related stocks with our FREE daily email newsletter.